Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study

Samankaltaisia teoksia

• Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
  Tekijä: Zhang, Hongyan, et al.
  Julkaistu: (2016)
• Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
  Tekijä: Chen, Ching-Yen, et al.
  Julkaistu: (2018)
• Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study()
  Tekijä: Pandina, Gahan, et al.
  Julkaistu: (2020)
• Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
  Tekijä: Yang, Fu De, et al.
  Julkaistu: (2017)
• Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
  Tekijä: Zhao, Jingping, et al.
  Julkaistu: (2017)